Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression. Materials and Methods We employed public glioma datasets, Repository of Molecular Brain Neoplasia Data and The Cancer Genome Atlas, to analyze SEMA3AmRNA expression in human GBM specimens. We also evaluated for protein expression level of SEMA3A via tissue microarray (TMA) analysis. Cell migration and proliferation kinetics were assessed in various GBM patient-derived cells (PDCs) and U87-MG cell-line for SEMA3A antibody efficacy. GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo. Results By combining bioinformatics and TMA analysis, we discovered that SEMA3A is highly expressed in human GBM specimens compared to non-neoplastic tissues. We developed three different anti-SEMA3A antibodies, in fully human IgG form, through screening phagedisplayed synthetic antibody library using a classical panning method. Neutralization of SEMA3A significantly reduced migration and proliferation capabilities of PDCs and U87-MG cell line in vitro. In PDX models, treatment with anti-SEMA3A antibody exhibited notable tumor inhibitory effect through down-regulation of cellular proliferative kinetics and tumorassociated macrophages recruitment. Conclusion In present study, we demonstrated tumor inhibitory effect of SEMA3A antibody in GBM progression and present its potential relevance as a therapeutic agent in a clinical framework.
Abstract
Purpose Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression. Materials and Methods We employed public glioma datasets, Repository of Molecular Brain Neoplasia Data and The Cancer Genome Atlas, to analyze SEMA3AmRNA expression in human GBM specimens. We also evaluated for protein expression level of SEMA3A via tissue microarray (TMA) analysis. Cell migration and proliferation kinetics were assessed in various GBM patient-derived cells (PDCs) and U87-MG cell-line for SEMA3A antibody efficacy. GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo. Results By combining bioinformatics and TMA analysis, we discovered that SEMA3A is highly expressed in human GBM specimens compared to non-neoplastic tissues. We developed three different anti-SEMA3A antibodies, in fully human IgG form, through screening phagedisplayed synthetic antibody library using a classical panning method. Neutralization of SEMA3A significantly reduced migration and proliferation capabilities of PDCs and U87-MG cell line in vitro. In PDX models, treatment with anti-SEMA3A antibody exhibited notable tumor inhibitory effect through down-regulation of cellular proliferative kinetics and tumorassociated macrophages recruitment. Conclusion In present study, we demonstrated tumor inhibitory effect of SEMA3A antibody in GBM progression and present its potential relevance as a therapeutic agent in a clinical framework.
참고문헌 (29)
- Adamson C, "Glioblastoma multiforme: a review of where we have been and where we are going", Expert Opin Investig Drugs, 18, pp.1061~1083 (2009)[DOI]
- Louis DN, "The 2007 WHO classification of tumours of the central nervous system", Acta Neuropathol, 114, pp.97~109 (2007)[DOI]
- Reardon DA, "Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents", Oncologist, 11, pp.152~164 (2006)[DOI]
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)[DOI]
- Linger RM, "TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer", Adv Cancer Res, 100, pp.35~83 (2008)
- Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)[DOI]
- Dunn GP, "Emerging insights into the molecular and cellular basis of glioblastoma", Genes Dev, 26, pp.756~784 (2012)[DOI]
- Zwick E, "Receptor tyrosine kinase signalling as a target for cancer intervention strategies", Endocr Relat Cancer, 8, pp.161~173 (2001)[DOI]
- Herbst RS, "Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy", Cancer, 94, pp.1593~1611 (2002)[DOI]
- Sliwkowski MX, "Antibody therapeutics in cancer", Science, 341, pp.1192~1198 (2013)[DOI]
- Tamagnone L, "Signalling by semaphorin receptors: cell guidance and beyond", Trends Cell Biol, 10, pp.377~383 (2000)[DOI]
- Kruger RP, "Semaphorins command cells to move", Nat Rev Mol Cell Biol, 6, pp.789~800 (2005)[DOI]
- Neufeld G, "Semaphorins in angiogenesis and tumor progression", Cold Spring Harb Perspect Med, 2, pp.a006718~ (2012)
- Luo Y, "Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones", Cell, 75, pp.217~227 (1993)[DOI]
- Kigel B, "Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells", PLoS One, 3, pp.e3287~ (2008)[DOI]
- Acevedo LM, "Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor", Blood, 111, pp.2674~2680 (2008)[DOI]
- Muller MW, "Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer", Int J Cancer, 121, pp.2421~2433 (2007)[DOI]
- Bagci T, "Autocrine sema-phorin 3A signaling promotes glioblastoma dispersal", Oncogene, 28, pp.3537~3550 (2009)[DOI]
- Treps L, "Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma", Oncogene, 35, pp.2615~2623 (2016)[DOI]
- Hu ZQ, "Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection", Oncotarget, 7, pp.51733~51746 (2016)
- Kretzschmar T, "Antibody discovery: phage display", Curr Opin Biotechnol, 13, pp.598~602 (2002)[DOI]
- Hoogenboom HR, "Antibody phage display technology and its applications", Immunotechnology, 4, pp.1~20 (1998)[DOI]
- Lee J, "Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines", Cancer Cell, 9, pp.391~403 (2006)[DOI]
- Hye Young Yang, "Construction of a Large Synthetic Human scFv Library with Six Diversified CDRs and High Functional Diversity", Molecules and Cells, 27(2), pp.225~235 (2009), 한국분자세포생물학회
- Shinohara H, "Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation", Cancer Res, 60, pp.1766~1772 (2000)
- Casazza A, "Impeding macrophage entry into hypoxic tumor areas by Sema3A", Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity, 2013, pp.24, 695~709
- Rivera LB, "Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity", Cancer Cell, 24, pp.687~689 (2013)[DOI]
- Solinas G, "Tumorassociated macrophages (TAM) as major players of the cancer- related inflammation", J Leukoc Biol, 86, pp.1065~1073 (2009)[DOI]
- Cerani A, "Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1", Cell Metab, 18, pp.505~518 (2013)[DOI]